Mark Zitter, MBA, Discusses Implications of Co-Pay Offset Programs for Managed Care

In this video, Mark Zitter, MBA, talks about the implications of Co-Pay Offset Programs for managed care. "Co-pay programs affect managed care very differently depending on the nature of the program," says Zitter. "These programs are tremendously varied."

Related Videos

Related Content

Advertisement

August 1st 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

August 1st 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

August 1st 2025

Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.

August 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.

August 1st 2025

Patients With Dry Eye Have More Treatment Options Than Ever Before: A Q&A With Mina Massaro-Giordano, MD

Julia Bonavitacola Mina Massaro-Giordano, MD

The symptoms of dry eye are multifactorial, says Mina Massaro-Giordano, MD, making identifying and treating dry eye important for quality of life.

August 1st 2025

Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

Related Content

Advertisement

August 1st 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

August 1st 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

August 1st 2025

Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.

August 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.

August 1st 2025

Patients With Dry Eye Have More Treatment Options Than Ever Before: A Q&A With Mina Massaro-Giordano, MD

Julia Bonavitacola Mina Massaro-Giordano, MD

The symptoms of dry eye are multifactorial, says Mina Massaro-Giordano, MD, making identifying and treating dry eye important for quality of life.

August 1st 2025

Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.